LON Stock News Loncor Resources Inc (LON) 0.11 08/02/2014 02

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Loncor Resources Inc (LON) 0.11 $LON

Loncor Decides to Voluntarily Delist from the NYSE MKT
Marketwire - Wed Apr 02, 7:31AM CDT
Loncor Resources Inc. (the "Company" or "Loncor" (TSX: LN)(NYSE MKT: LON) announces that it is voluntarily delisting from the NYSE MKT LLC (the "NYSE MKT". As noted in the Company's press release of March 10, 2014, the Company received a letter from the NYSE MKT advising that the NYSE MKT has determined that the Company is currently not in compliance with Sections 1002(c) and 1003(c)(i) of the NYSE MKT Company Guide.

Loncor Resources Form 20-F Annual Report Filed on Edgar; Annual Financials Filed on Sedar
Marketwire - Tue Apr 01, 12:56PM CDT
Loncor Resources Inc. (the "Company" or "Loncor" (TSX: LN)(NYSE MKT: LON) announces that an annual report on Form 20-F has been filed by the Company with the U.S. Securities and Exchange Commission, which report includes the Company's 2013 annual audited consolidated financial statements and related management's discussion and analysis. This report is available for viewing and retrieval through Edgar at www.sec.gov.

Loncor Resources Provides Corporate Update
Marketwire - Mon Mar 10, 7:16PM CDT
As required by the rules of the NYSE MKT LLC (the "NYSE MKT", Loncor Resources Inc. (the "Company" or "Loncor" (TSX: LN)(NYSE MKT: LON) reports that it has received a letter from the NYSE MKT advising that the NYSE MKT has determined that the Company is currently not in compliance with Sections 1002(c) and 1003(c)(i) of the NYSE MKT's Company Guide, relating to the Company's reduced exploration effort (as previously reported, the Company has reduced its exploration effort and overhead costs until market conditions improve). The Company must submit a plan of compliance to the NYSE MKT by April 2, 2014 addressing how it intends to regain compliance by March 4, 2015.

Loncor Resources Updates Exploration Activities at its Ngayu Project in D.R. Congo
Marketwire - Wed Jul 31, 6:01AM CDT
Loncor Resources Inc. (the "Company" or "Loncor" (TSX: LN)(NYSE MKT: LON) is pleased to provide an update on its exploration activities at its Ngayu Gold Project in the northeastern Democratic Republic of the Congo (the "DRC".

Loncor Resources Announces Election of Directors
Marketwire - Thu Jun 27, 8:28PM CDT
Loncor Resources Inc. (the "Company" or "Loncor" (TSX: LN) (NYSE MKT: LON) announces that the six nominees listed in the Company's management information circular for the annual and special meeting of shareholders of the Company (the "Meeting" held on Thursday, June 27, 2013 were elected at the Meeting as directors of Loncor. The vote was conducted by a show of hands. The detailed results of the votes received by proxy are set out below:

Loncor Resources Moves to Toronto Stock Exchange
Marketwire - Thu Apr 25, 7:58AM CDT
Loncor Resources Inc. (the "Company" or "Loncor" (TSX VENTURE: LN)(NYSE MKT: LON)(NYSE Amex: LON) is pleased to announce that its common shares will begin trading on the Toronto Stock Exchange ("TSX" under the symbol "LN" effective Friday April 26, 2013 and will be delisted from the TSX Venture Exchange ("TSX-V" at the same time. Loncor began trading on the TSX-V in December 2008 and has been listed on NYSE-MKT (formerly the AMEX market) under the trading symbol "LON" since April 2011. The Company has 73,439,732 common shares issued and outstanding.

Loncor Resources Completes the First Phase of IP Surveys at its Nagasa Prospect and Defines Priority Drill Targets
Marketwire - Tue Apr 23, 8:22AM CDT
Loncor Resources Inc. (the "Company" or "Loncor" (TSX VENTURE: LN)(NYSE MKT: LON)(NYSE Amex: LON) is pleased to announce the results of Induced Polarisation (IP) surveys at the Company's Nagasa prospect, Ngayu Gold Project, northeastern Democratic Republic of the Congo (the "DRC".

Loncor Resources Increases and Upgrades Mineral Resources at Its Makapela Prospect in the DRC
Marketwire - Tue Apr 09, 8:33AM CDT
Loncor Resources Inc. (the "Company" or "Loncor" (TSX VENTURE: LN)(NYSE MKT: LON)(NYSE Amex: LON) is pleased to announce increases and upgrades of Mineral Resources at the Company's Makapela prospect, Ngayu Gold Project, northeastern Democratic Republic of the Congo (the "DRC". These Mineral Resources incorporate an additional 13 core holes from the initial, Inferred-only maiden resource of 1.00 million ounces (4.10 million tonnes grading 7.59 g/t Au using a 2.75 g/t Au cut-off grade) that was announced by the Company in a press release dated May 29, 2012. This current resource statement has been undertaken as part of the Preliminary Economic Assessment ("PEA" currently being undertaken by a number of independent consultants at Makapela with completion slated for the end of May 2013.

Loncor Resources Form 20-F Filed on EDGAR; Annual Financials Filed on SEDAR
Marketwire - Mon Apr 01, 12:48PM CDT
Loncor Resources Inc. (the "Company" or "Loncor" (TSX VENTURE: LN)(NYSE MKT: LON)(NYSE Amex: LON) announces that an annual report on Form 20-F has been filed by the Company with the U.S. Securities and Exchange Commission, which report includes the Company's 2012 annual audited consolidated financial statements and related management's discussion and analysis. This report is available for viewing and retrieval through Edgar at www.sec.gov.

Loncor Announces Resignation of Director
Marketwire - Mon Mar 04, 8:58AM CST
Loncor Resources Inc. (the "Company" or "Loncor" (TSX VENTURE: LN)(NYSE MKT: LON)(NYSE Amex: LON) announces the resignation of Simon Village from the Company's board of directors effective immediately.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Energy Hits Legal Snag: Investors Called to Act

Updated Category News Views 79

Fluence Energy Faces a Securities Fraud Challenge It's like watching a slow-motion train wreck. Fluence Energy, Inc. (NASDAQ: FLNC) now finds itself in the crosshairs of a securities fraud class action lawsuit. Apparently, someone was playing fast and loose with the truth concerning their financial guidance. The period in question stretches from November 24, 2025, to...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 421

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Vantrue's Black Friday Dash Cam Deals: Save up to 44%

Updated Category News Views 72

Kicking Off Early Black Friday with Dash Cam Bargains In a bid to stay ahead of the holiday shopping rush, Vantrue announced its early Black Friday campaign with a range of discounts designed to capture the interest of road warriors and casual drivers alike. From November 1 to November 21, 2026, Vantrue is inviting bargain hunters to explore their offerings—culminating...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 140

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 93

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 149

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 312

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
RYBREVANT's Promising Results in HNSCC Treatment

Updated Category News Views 87

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Continue Reading

Top 5 Most Recently Viewed Articles

Kohl's Stock Plummets Amid Retail Challenges and Restructuring

Updated Category News Views 589

Kohl's Corporation Faces Significant Challenges Kohl's Corporation (NYSE: KSS) has recently seen its stock plummet to a concerning 52-week low of $13.61. This decline paints a grim picture of the current retail environment, where shifting consumer habits and fierce competition play a pivotal role. Priced at just 0.4 times book value and boasting a generous 14.5% dividend...

Continue Reading
Rapid Micro Biosystems Achieves Record Growth and Future Outlook

Updated Category News Views 136

Financial Performance Highlights for Rapid Micro Biosystems Rapid Micro Biosystems, Inc. (NASDAQ: RPID) has announced impressive results for the fourth quarter and the entire fiscal year of 2024. The company recorded a total revenue of $8.2 million in the fourth quarter, marking a 30% increase compared to the same period in 2023. Likewise, the full year revenue reached...

Continue Reading
ALZpath and Siemens Team Up for Advanced Alzheimer's Testing

Updated Category News Views 265

ALZpath and Siemens Healthineers Form Strategic Partnership ALZpath is thrilled to announce a significant licensing agreement with Siemens Healthineers. This collaboration marks a pivotal enhancement in the accessibility of diagnostic testing for Alzheimer's disease. The agreement involves the use of ALZpath's proprietary pTau217 antibody, a remarkable tool for...

Continue Reading
Generate:Biomedicines Showcases Promising Results for GB-0895

Updated Category News Views 495

Results from Phase 1 Trials of GB-0895 Unveiled Generate:Biomedicines is making notable headlines with its innovative drug GB-0895. This cutting-edge treatment is an ultra-high affinity anti-TSLP monoclonal antibody, specifically designed for individuals grappling with asthma. With a unique formulation, GB-0895 offers a prolonged half-life and sustained pharmacological...

Continue Reading
Driving Growth in Natural Stone Market and Its Future

Updated Category News Views 226

Steady Growth in the Natural Stone Market The natural stone market is on a promising upward trajectory, predicted to rise from USD 37.89 billion to USD 47.63 billion by a future date, indicating a compound annual growth rate (CAGR) of 4.68%. Various factors are driving this growth, most notably the intense infrastructure investment blooming worldwide. The construction...

Continue Reading